COVID-19 Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-Based Study

Overview

Journal Vaccines (Basel)

Date 2024 May 25

PMID 38793704

Authors

Tal Gazitt

Lihi Eder

Walid Saliba

Nili Stein

Ilan Feldhamer

Arnon Dov Cohen

Devy Zisman

Affiliations

Soon will be listed here.

Abstract

Limited information is available on the effectiveness of COVID-19 vaccination in patients with psoriasis and psoriatic arthritis (psoriatic disease (PsD)). The objective of our research was to assess the effectiveness of mRNA COVID-19 vaccination in preventing SARS-CoV-2 positivity and severe infection in a cohort of patients with PsD and the association of immunosuppressants on SARS-CoV-2 infection-related outcomes from December 2020 to December 2021. Vaccine effectiveness was assessed in a matched nested case control study using conditional logistic regression adjusted for demographics, comorbidities and immunosuppressant use. Study outcomes included SARS-CoV-2 positivity and severe COVID-19 (moderate-to-severe COVID-19-related hospitalizations or death). At least one dose of mRNA COVID-19 vaccine was associated with reduced risk of SARS-CoV-2 positivity and severe COVID-19 (OR = 0.41 (95% CI, 0.38-0.43) and OR = 0.15 (95% CI, 0.11-0.20), respectively). A more significant effect was found among patients who received three vaccines doses compared with those who did not receive any (OR (for positive SARS-CoV-2) = 0.13 (95% CI, 0.12-0.15) and OR (for severe disease) = 0.02 (0.01-0.05)). Etanercept and methotrexate were associated with higher risk of SARS-CoV-2 positivity (1.58 (1.19-2.10), = 0.001 and 1.25 (1.03-1.51), = 0.03, respectively). In conclusion, our results show that mRNA COVID-19 vaccines are effective in reducing both infection and severe COVID-19-related outcomes.

References

Machado P, Schafer M, Mahil S, Liew J, Gossec L, Dand N . Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Ann Rheum Dis. 2023; 82(5):698-709. PMC: 10176347. DOI: 10.1136/ard-2022-223499. View

Gil-Vila A, Ravichandran N, Selva-OCallaghan A, Sen P, Nune A, Gaur P . COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. Muscle Nerve. 2022; 66(4):426-437. PMC: 9349921. DOI: 10.1002/mus.27681. View

Izadi Z, Brenner E, Mahil S, Dand N, Yiu Z, Yates M . Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open. 2021; 4(10):e2129639. PMC: 8524310. DOI: 10.1001/jamanetworkopen.2021.29639. View

Jordan R, Adab P, Cheng K . Covid-19: risk factors for severe disease and death. BMJ. 2020; 368:m1198. DOI: 10.1136/bmj.m1198. View

Gazitt T, Pesachov J, Lavi I, Elias M, Haddad A, Feldhamer I . The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study. Arthritis Res Ther. 2022; 24(1):16. PMC: 8740055. DOI: 10.1186/s13075-021-02703-8. View

Izmirly P, Kim M, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine K . Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol. 2021; 74(2):284-294. PMC: 8426963. DOI: 10.1002/art.41937. View

Galmiche S, Luong Nguyen L, Tartour E, de Lamballerie X, Wittkop L, Loubet P . Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect. 2022; 28(2):163-177. PMC: 8595936. DOI: 10.1016/j.cmi.2021.09.036. View

Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V . Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?. Front Med (Lausanne). 2022; 9:811829. PMC: 8918942. DOI: 10.3389/fmed.2022.811829. View

Boyarsky B, Ruddy J, Connolly C, Ou M, Werbel W, Garonzik-Wang J . Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021; 80(8):1098-1099. PMC: 8822300. DOI: 10.1136/annrheumdis-2021-220289. View

10.

Eder L, Cohen A, Feldhamer I, Greenberg-Dotan S, Batat E, Zisman D . The epidemiology of psoriatic arthritis in Israel - a population-based study. Arthritis Res Ther. 2018; 20(1):3. PMC: 5795280. DOI: 10.1186/s13075-017-1497-4. View

11.

Spiera R, Jinich S, Jannat-Khah D . Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021; 80(10):1357-1359. DOI: 10.1136/annrheumdis-2021-220604. View

12.

Simon D, Tascilar K, Fagni F, Kronke G, Kleyer A, Meder C . SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021; 80(10):1312-1316. PMC: 8103562. DOI: 10.1136/annrheumdis-2021-220461. View

13.

Dolinger M, Person H, Smith R, Jarchin L, Pittman N, Dubinsky M . Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab. J Pediatr Gastroenterol Nutr. 2020; 71(2):153-155. PMC: 7268863. DOI: 10.1097/MPG.0000000000002809. View

14.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y . Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1):110-118. PMC: 7152876. DOI: 10.1016/j.jaci.2020.04.006. View

15.

Chhibba T, Targownik L . Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?. Lancet Gastroenterol Hepatol. 2022; 7(4):280-282. PMC: 8813199. DOI: 10.1016/S2468-1253(22)00040-1. View

16.

Frommert L, Arumahandi de Silva A, Zernicke J, Scholz V, Braun T, Jeworowski L . Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease. RMD Open. 2023; 8(2). PMC: 9729845. DOI: 10.1136/rmdopen-2022-002650. View

17.

Cohen A, Dreiher J, Shapiro Y, Vidavsky L, Vardy D, Davidovici B . Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008; 22(5):585-9. DOI: 10.1111/j.1468-3083.2008.02636.x. View

18.

Curtis J, Johnson S, Anthony D, Arasaratnam R, Baden L, Bass A . American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol. 2021; 73(10):e60-e75. PMC: 8426685. DOI: 10.1002/art.41928. View

19.

Haberman R, Herati R, Simon D, Samanovic M, Blank R, Tuen M . Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021; 80(10):1339-1344. PMC: 8219484. DOI: 10.1136/annrheumdis-2021-220597. View

20.

Brenner E, Ungaro R, Gearry R, Kaplan G, Kissous-Hunt M, Lewis J . Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020; 159(2):481-491.e3. PMC: 7233252. DOI: 10.1053/j.gastro.2020.05.032. View